Researchers found that the biosimilar offered only limited efficacy when used for induction of remission in patients with moderate to severe ulcerative colitis that was refractory to treatment with steroids.
A retrospective, observational study, newly published in Intestinal Research, reports the first real-world experience with India’s first available biosimilar adalimumab, Exemptia (made by Zydus Cadila), in patients with ulcerative colitis (UC). The researchers found that the biosimilar offered only limited efficacy when used for induction of remission in patients with moderate to severe UC that was refractory to treatment with steroids.
In India, the use of biologic drugs has been limited by the high cost of treatment; the availability of a biosimilar adalimumab, referencing Humira, has expanded access to treatment. However, few data on the safety and efficacy of Exemptia have been available thus far, and concerns about the acquisition or reactivation of tuberculosis in patients in developing countries, like India, have persisted.
The research team sought to evaluate the treatment outcomes of patients receiving the biosimilar adalimumab for moderate to severe UC. The study, conducted between June 2015 and December 2016, included 29 patients who each received a total of 5 subcutaneous injections of Exemptia (160 mg at week 0, 80 mg at week 2, and 40 mg every other week from week 4 to week 8).
After induction with Exemptia, patients received maintenance azathioprine, and patients’ corticosteroids were tapered over a period of 2 to 3 months. Clinical response (a decrease in total Mayo score of at least 3 points or more than 30% from baseline, plus a decrease in rectal bleeding score by at least 1 point and an absolute rectal bleeding score of 0 or 1) and clinical remission (a total Mayo score of 2 points or less, with no individual score above 1 point) were determined at week 8.
At week 8, 7 patients (24.1%) showed a clinical response, and 1 patient (3.5%) had achieved clinical remission. The 8 responders were maintained on azathioprine. Among the 21 non-responding patients, 4 required colectomies, 1 patient died, and 1 patient was lost to follow-up.
Adverse events were noted in 4 patients: 2 patients had pulmonary tuberculosis, and 2 had tubercular pericardial effusion (1 of whom also had cardiac arrhythmia). Mild injection-site reactions occurred in 2 patients.
The authors conclude that Exemptia had only limited efficacy when used for induction of remission in patients with moderate to severe steroid-refractory UC. Furthermore, the authors note, “In developing countries such as India, where 40% of the population is exposed to tuberculosis (a majority of whom have latent tuberculosis), biologicals and biosimilars should be prescribed with caution.” Large, multi-center trials will be required to allow for a more robust examination of the role of the biosimilar adalimumab in the management of UC.
Reference
Midha V, Mahajan R, Mehta V, et al. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intestinal Research. 2018;16:83-89. http://dx.doi.org/10.5217/ir.2018.16.1.83. Published January 30, 2018. Accessed February 13, 2018.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.